Significantly Reduced Pain and Improved Function Following Short-Term Use of the BioWaveHOME High Frequency Neurostimulation System for Conservative Pain Management

Clinical White Paper August 2020 Lindsay Kleinwaks, Ph.D., Senior Associate, Regulatory Affairs Dave McGurl, Director, Regulatory Affairs.

Following two weeks of BioWaveHOME use, four hundred sixty three (463) subjects provided responses via returned surveys. The BioWaveHOME device provided subjects with statistically and clinically significant reductions in pain, with an average reduction in pain score of 3 points.